Forres

Quick links to important sections

Forres

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Forres

What is Forres? (Eperisone)

This section defines the fundamental identity, composition, and general purpose of the medicine Forres (Eperisone), excluding specific usage instructions or safety information.

Property Description
Active ingredient Eperisone hydrochloride
Form Film-coated tablets (Oral)
Pharmacological class Centrally Acting Skeletal Muscle Relaxant (CASMR)
Common purpose Alleviation of muscle stiffness and hypertonia
Origin Synthetic

What Type of Medicine is Forres and Its Active Component?

Forres is a prescription medicine containing the single active ingredient, Eperisone hydrochloride (INN: Eperisone), a synthetic compound classified as a Centrally Acting Skeletal Muscle Relaxant (CASMR). This means the medicine is specifically designed to manage muscle stiffness and hypertonus by influencing signals within the spinal cord. The drug entity contains a non-narcotic myorelaxant compound, Eperisone, which is chemically synthesized. The CASMR classification reflects its primary therapeutic focus on controlling the heightened motor neuron activity that leads to persistent muscle tension.


General Purpose: What Does Eperisone Help to Achieve?

The general purpose of this medicine is to alleviate the discomfort and restricted movement caused by skeletal muscle hypertonia—abnormal and chronic muscle stiffness or spasm. The compound is also noted for its ability to improve blood circulation in muscle tissues, alongside its primary action of relaxing the muscles. The medicine assists patients by addressing both muscle rigidity and local blood flow issues.

This general benefit stems from its unique dual action on the spinal cord, where it helps reduce the excessive nerve signals that cause muscles to involuntarily tighten. Eperisone is used for its efficacy in treating various conditions associated with muscle hypertonia. This action is widely recognized in clinical practice for patients experiencing conditions like persistent lower back tension or stiffness in the shoulder and neck regions.


High-Level Composition and Formulation Type

Forres is a single-entity product based on a synthetic origin, formulated as a film-coated tablet for systemic administration via the oral route. The composition consists solely of the active ingredient, Eperisone hydrochloride, combined with necessary pharmaceutical excipients (binders and coating materials) to ensure stability and proper absorption. In many regulatory contexts, Eperisone is clinically recognized for its favorable efficacy and tolerability profile compared to traditional muscle relaxants, making it a common choice where effective reduction of muscle tone is needed.

What side effects are possible with Forres?

Possible Side Effects and Safety Information

The safety profile of Forres (Eperisone hydrochloride) details adverse reactions organized by the physiological systems they affect, based strictly on authoritative governmental regulatory documents.

Adverse Reaction Scope

Adverse effects are broadly classified, with the most commonly reported reactions involving the Nervous System (e.g., drowsiness, dizziness, headache) and Gastrointestinal Disorders (e.g., nausea, gastric discomfort, loss of appetite, constipation, or diarrhea). General systemic effects like lassitude (weakness/fatigue) are also frequently documented.

Rare but Serious Adverse Reactions are explicitly noted in official labeling. These include Shock, severe Anaphylactoid symptoms (such as edema and respiratory distress), and life-threatening dermatological conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Patients are advised that immediate observation is necessary should symptoms suggesting these serious reactions, such as fever or rash, occur.

Population-Specific Safety Considerations

Regulatory information specifies caution for certain patient groups. Older adults may require dosage reduction or close monitoring due to potential impairment of physiological functions. Use during pregnancy is permitted only if the expected therapeutic benefit is determined to outweigh potential risks, as safety is not fully established. The medicine is generally not recommended during lactation. Caution is also required for patients with a history of liver function disorders as use may aggravate pre-existing hepatic dysfunction.

Eperisone is contraindicated in individuals with a known history of hypersensitivity to the drug. Furthermore, official safety documents recommend avoiding co-administration with other centrally acting muscle relaxants such as tolperisone HCl and methocarbamol due to a documented risk of visual disturbances.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived from official governmental regulatory documents regarding the recognition and required response to an overdose of Forres (Eperisone).

An overdose may manifest as an exacerbation of common neurological and systemic symptoms documented in official labeling, including significant drowsiness, generalized lassitude (malaise), and dizziness. Gastrointestinal symptoms, such as nausea and abdominal discomfort, may also be present.

Overdose carries the potential for severe, life-threatening outcomes, and documented cases of severe intoxication have reported major neurological events such as seizures and coma. In extreme cases, there is an associated risk of cardiotoxicity characterized by QTc interval prolongation.

Emergency Action Required Official Management Protocol
Seek emergency medical treatment immediately for any known or suspected overdose.
No specific antidote is known for Eperisone overdose, according to regulatory summaries.
Immediate medical help is also required for signs of severe adverse events, such as shock or anaphylactoid symptoms.
Management is limited to symptomatic and supportive treatment to maintain vital functions.

Official guidance strictly mandates that immediate medical attention must be sought for any suspected over-exposure due to the potential for severe CNS and cardiac complications. Specific considerations for accidental pediatric ingestion have also been documented, underscoring the severity of intoxication in this population.

Therapeutic Uses of Forres

Forres is commonly used to help manage symptoms of increased neurological or muscular activity and symptoms related to physical discomfort across multiple therapeutic domains. It is applied in addressing conditions marked by heightened muscular tension, including low back pain, cervical spondylosis, stiff shoulder, and spastic paralysis stemming from various causes. Its use is considered relevant for easing symptoms associated with both spinal conditions and neurological spasticity.

This medication is generally used to help manage symptom clusters that may become intense or disruptive arising from common musculoskeletal issues. It contributes to easing the overall symptom load, which may assist with maintaining a sense of stability when symptoms are more noticeable during symptomatic periods. It is relevant in contexts involving heightened systemic burden, such as conditions associated with trauma or postoperative discomfort, where tension interferes with daily functioning. This medicine may assist with managing rigidity and tension in conditions presenting with significant symptomatic burden.

“It is applied in addressing symptom clusters that may become intense or disruptive, helping patients cope more steadily with symptom fluctuations.”

Quick Fact: Symptomatic Focus This medicine is commonly used to help with managing rigidity and tension in conditions presenting with significant symptomatic burden, such as spastic spinal paralysis or sequelae from cerebrovascular disorders.

Regulatory References

  1. Official Japanese Drug Information Sheet for Eperisone

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Forres

Regulatory documents define eligibility for Forres (Eperisone) based on specific patient demographics and pre-existing conditions.

Classification Population or Condition Regulatory Status
Contraindicated Patients with a known hypersensitivity to Eperisone hydrochloride or any component of the formulation. Absolute Prohibition
Not Recommended Children (Pediatric Population) Safety and efficacy not established
Not Recommended Breastfeeding (Lactation) women Discontinuation of nursing is required if treatment is necessary
Conditional Use Pregnant women Use only if benefits officially outweigh the possible risks
Conditional Use Elderly patients Requires careful administration and potential dosage adjustment
Restricted Use Patients with Hepatic Disorders Requires careful administration and monitoring for aggravation
Restricted Use Patients with Renal Disorders Requires careful observation; some sources cite contraindication in severe impairment

The primary population with established use for Eperisone is adults with muscular hypertonia. Non-eligibility or restricted use is imposed by regulatory authorities across specific vulnerable groups. Hypersensitivity to the drug is the only absolute contraindication, while use in children is not recommended due to a lack of established safety and efficacy data. Pregnant women, the elderly, and those with hepatic or renal impairment are subject to conditional use, requiring specific caution and risk assessment as stipulated in the official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Forres (Eperisone hydrochloride) identifies specific interaction patterns, primarily centered on pharmacodynamic effects and metabolic constraints.

Documented Interaction Patterns

Category Documented Interaction Entities and Official Outcomes
Pharmacodynamic Interactions Co-administration with similar Centrally Acting Muscle Relaxants, such as Methocarbamol or Tolperisone hydrochloride, may be associated with reports of disturbances in ocular accommodation (visual effects).
Drug-Substance Restriction Treatment requires the mandatory avoidance of alcohol consumption (ethanol) due to the risk of additive Central Nervous System (CNS) effects, leading to excessive drowsiness, and potential aggravation of hepatic side effects.
Pharmacokinetic Profile Formal regulatory studies indicate no clinically significant change in Eperisone plasma concentrations (AUC or Cmax) when co-administered with the Non-Steroidal Anti-inflammatory Drug (NSAID) Aceclofenac.

Regulatory Constraints

The most significant constraints are related to CNS-acting agents and metabolic risk. Official prescribing information states that the medicine must be used with caution in patients with pre-existing hepatic disorders. This caution is tied to the drug’s metabolism and the potential for it to aggravate existing liver impairment, an important population-specific consideration. No medicinal product is formally designated as a contraindicated combination, and no specific timing separation rule is specified for co-administered drugs.

Mechanism of Action

Forres functions as a centrally acting agent that modulates neuronal and vascular activity. Its primary molecular targets include voltage-gated sodium channels and calcium ion channels, where it acts as a channel blocker. In the central nervous system, Forres inhibits neuronal excitability by reducing calcium ion influx into neural terminals, decreasing the release of excitatory neurotransmitters. This downstream action diminishes the transmission of nerve impulses that mediate muscle contractions and concurrently suppresses both mono- and polysynaptic reflexes within the spinal cord. Peripherally, Forres exerts a vasodilatory effect through the relaxation of vascular smooth muscle fibers. This systemic physiological consequence results in increased local tissue perfusion, modulating the supply of oxygen and removal of metabolic byproducts from muscle tissues.

Dosage and Administration Information

How to Use Forres

Forres, which contains Eperisone hydrochloride, is approved for oral administration and is formulated as a film-coated tablet. The established usage pattern defines the specific dose, frequency, and timing required for proper administration according to regulatory guidelines. This ensures the consistent delivery of the active ingredient as intended by official labeling.


Standard Administration Protocol

The medicine is typically used in a structured, daily regimen. The standard total daily dose for adults is 150 mg of Eperisone hydrochloride.

Usage Parameter Regulatory Instruction
Route of Administration Oral, via swallowing film-coated tablets.
Dose Division Administered in three equal divided doses.
Timing Each dose is taken after a main meal (e.g., breakfast, lunch, and dinner).
Tablet Integrity Tablets must be swallowed whole with water, not crushed or chewed.

Usage Patterns for Specific Populations

Official prescribing information includes instructions for adjusting the standard regimen based on patient factors, emphasizing that the medicine is not used uniformly across all populations. For older adults, the dosage should be adjusted (often reduced) and closely monitored due to potential physiological changes. Furthermore, use in the pediatric population is not recommended as the safety profile for children has not been established.

Handling Missed Doses

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients must not take a double dose to compensate for the one that was missed.

Recent Clinical Evidence

Research Evidence for Forres (Eperisone)

This overview summarizes the official clinical research and trials that characterize the role of Forres (Eperisone), focusing on the types of studies conducted, what outcomes they measured, and where scientific certainty remains low. This information is drawn from authoritative governmental and peer-reviewed scientific sources and does not constitute medical advice or instruction.

Evidence for Musculoskeletal Spasm, Including Low Back Pain

Research examining Forres for musculoskeletal spasm, particularly associated with acute low back pain (LBP), was studied for short-term changes in symptoms. Researchers conducted short-term randomized, double-blind, placebo-controlled trials (RCTs). This type of research structure contributes to the assessment of short-term outcomes related to physical discomfort during acute episodes. The main populations studied included adults with low back pain linked to specific musculoskeletal conditions, as defined by the trials.

The studies monitored changes in outcomes over defined time intervals, usually lasting 7 to 14 days. Research has explored outcomes related to physical discomfort, monitoring patient-reported pain intensity using standardized tools and objective measures of spinal mobility. Findings describe patterns observed in the studies where patient pain measurements were compared to those recorded for patients taking an inactive placebo. Comparative studies against other treatments, like non-steroidal anti-inflammatory drugs (NSAIDs) or other muscle relaxants, examined observed changes in pain and function compared to the agents being studied.

Research on Spasticity and Neurological Muscle Tone

Eperisone was evaluated in research settings involving conditions marked by functional limitations, such as spastic paralysis resulting from cerebrovascular disorders (like stroke) or myelopathy. These studies explored Eperisone as part of a research context involving fluctuating or unstable symptoms. The studies examined outcomes related to systemic or functional imbalance, including objective assessments of the intensity of spasticity using scales and the presence of pathological reflexes. Functional outcomes reflecting daily functioning or activity level were also monitored.

Evidence Gaps and Areas for Further Research

Scientific analysis points to several research limitations. Follow-up durations were limited in many key trials, making it difficult to draw conclusions about sustained response or any effect beyond the acute treatment phase. Sample sizes were modest in some of the more complex studies, particularly those focused on spasticity, meaning that subgroup findings are uncertain. Comparative evidence is lacking for certain patient subgroups and long-term treatment strategies. This highlights that while research exists and studies describe patterns observed so far, a more complete understanding remains to be established, especially concerning chronic condition management.

Key Studies & References

  1. EPERISONE HYDROCHLORIDE TABLETS 50mg (Regulatory Information Sheet/Drug Label for Indication and Use)

Frequently Asked Questions (FAQ)

Common questions about Forres (FAQ)

Q: What happens if I stop taking Forres suddenly?

Official drug information sheets state that patients should not stop taking the medicine unless instructed to do so by a healthcare professional. Forres is part of a structured treatment regimen, and regulatory documents advise against self-discontinuation.

Q: Can Forres interact with over-the-counter pain relievers?

Regulatory documents have specifically examined the co-administration of Forres with the NSAID Aceclofenac, finding no clinically significant change in how the body processes Forres. Official prescribing information emphasizes the importance of informing a healthcare professional about all concomitant use of non-prescription medicines, vitamins, and supplements.

Q: Is Forres safe for people with kidney problems?

Official information indicates that use in patients with kidney problems requires careful observation and monitoring by a healthcare provider. Some regulatory sources also cite an absolute prohibition, or contraindication, in cases where kidney impairment is considered severe. This caution relates to the drug's metabolism and processing within the body.

Q: Can Forres interfere with birth control pills?

Studies on the drug’s metabolism suggest that it is not processed through the main liver enzyme pathways that typically mediate interactions with hormonal contraceptives. Regulatory and research data generally show no clinically significant interaction documented for hormonal contraceptives.

Q: Is Forres a type of antibiotic?

No, Forres is not an antibiotic. According to the official product information, it is classified as a Centrally Acting Skeletal Muscle Relaxant (CASMR). This means its primary function is to help manage muscle stiffness and hypertonia by influencing nerve signals.

Q: Is Forres a controlled substance?

The drug is generally classified internationally as a Prescription Only Medicine. Regulatory lists in jurisdictions like the US typically do not classify the active ingredient, Eperisone, as a scheduled controlled substance.

Q: Is it common to feel tired after taking Forres?

Official safety documents list lassitude as one of the commonly documented adverse reactions. Lassitude refers to a state of general weakness or fatigue. The occurrence of such symptoms is information a patient may choose to discuss with their healthcare professional.

Q: Will I feel the effect of Forres right away?

Clinical trials for conditions like acute low back pain typically monitored and measured changes in symptoms over defined time intervals, usually lasting 7 to 14 days. This indicates that the measured therapeutic effect is generally evaluated over a period of days or weeks, rather than immediately.

Q: How long can a person stay on Forres?

Regulatory summaries of clinical trials indicate that follow-up durations were often limited in key studies. This means that while the medicine is established for short-term use, evidence is not fully established regarding sustained response or effects beyond the acute phase of treatment.

Q: Does Forres have a 'Black Box Warning' from the FDA?

The active ingredient in Forres, Eperisone, is not currently approved for use by the Food and Drug Administration (FDA) in the United States. Since it is not an FDA-approved drug, it does not carry an FDA Black Box Warning.

Q: Is Forres known to be addictive?

Forres contains Eperisone, which is officially described in regulatory documents as a non-narcotic myorelaxant compound.

Q: Why is Forres prescribed for more than one condition?

The mechanism of the drug involves a dual action that addresses two different aspects of muscle conditions. It acts on the central nervous system to help reduce nerve signals that cause muscle stiffness and also has an effect on local blood circulation to muscle tissues.

Q: Can Forres affect blood pressure?

The drug’s mechanism of action includes a vasodilatory effect, which means it causes relaxation of the vascular smooth muscle fibers. Some official safety information also mentions hypotension (low blood pressure) as a potential, though rare, adverse reaction.

Q: Is there a generic version of Forres available?

The active ingredient, Eperisone hydrochloride, is available under multiple brand names globally and is identified with various generic names by regulatory bodies. The availability of a specific generic version is dependent on local regulatory and market conditions.

Q: How is the dose of Forres typically decided?

Official prescribing information states that while there is a standard daily regimen, the dosage should be adjusted based on the specific condition being addressed. A patient's age and overall symptoms are also listed as factors that determine the final administered dose.

Q: Are there any skin reactions linked to Forres?

Official drug documentation lists common skin reactions like rash, itch, and redness (erythema). Furthermore, rare but serious dermatological conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are explicitly noted in safety information.

Q: Is Forres considered a long-term treatment option?

Regulatory summaries of clinical trials indicate that follow-up durations were limited in many key studies. Due to this evidence gap, a complete understanding of the drug's effectiveness or safety for sustained, long-term chronic condition management remains to be established.

Q: Does the time of day matter when taking Forres?

The standard regimen specifies that the medicine should be taken in three equal divided doses, with each dose administered after a main meal. This means the timing of administration is tied to your eating schedule, ensuring consistent presence in the body.

How should Forres be stored and disposed of?

The official regulatory requirements for storing Forres (Eperisone hydrochloride) tablets are designed to protect the medicine's stability and prevent accidental ingestion.

Storage Conditions

Requirement Official Rule
Temperature Store at room temperature, typically not exceeding 30 C (30 C).
Protection Protect from light and moisture; keep in a cool, dry, and dark place.
Safety Keep out of the reach of children.
Prohibited Avoid storage in areas of direct sunlight, heat, or high humidity.

Disposal Instructions

Disposal must comply with environmental protection guidelines. The medicine must not be discharged into sewer systems or drains to prevent water contamination. Unused or expired tablets should be promptly discarded and should not be stored for later use. The preferred disposal method is through an authorized drug take-back program. If this is unavailable, non-flush list medicines can be mixed with an unappealing substance (like dirt or coffee grounds) and sealed in a container before placing in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Forres found in:

A-Z Index: